15% OFF $150+· CodeFALL15
Ends October 15Shop now
Lot certificates published
Discreet shipping

Compound monograph

SHU9119

SHU9119 is a cyclic lactam melanocortin analog whose receptor behaviour is subtype-dependent: antagonist at some melanocortin receptors and agonist at others.

Published: 2026-09-13Literature/identifier verification: 2026-09-13

01

Identity & nomenclature

SHU9119 is a cyclic lactam melanocortin analog whose receptor behaviour is subtype-dependent: antagonist at some melanocortin receptors and agonist at others.

SHU9119 shares the Melanotan II ring architecture and differs by a single substitution, D-Phe to D-2-Nal, a net C4H2 or 50.0157 Da. Shared ring architecture does not mean shared pharmacological direction — see structuralNotes. Calling it 'the melanocortin blocker' conceals the central experimental limitation of the compound.

Declared aliases and development codes: SHU-9119, SHU 9119.

02

Molecular properties

Molecular formulaC54H71N15O9
Molecular mass1074.26 Da
CAS Registry Number168482-23-3
PubChem CID6440621
Three-letter sequenceAc–Nle–Asp–His–D-2-Nal–Arg–Trp–Lys–NH2

Seven residues closed by a LACTAM between the Asp2 side-chain carboxyl and the Lys7 epsilon-amino group. D-2-Nal is 3-(naphthalen-2-yl)-D-alanine, one residue. No disulfide, no head-to-tail closure, and no safe linear string.

03

Structural characteristics

The original structure-activity work reports it as a potent MC4R antagonist and a less potent MC3R antagonist, both with minimal agonist activity, while behaving as a FULL AGONIST at MC1 and MC5 receptors. It is therefore not a pan-melanocortin antagonist, and its antagonism must not be transferred from MC4R to every experiment involving a melanocortin receptor. Receptor-bound structures exist at both MC4R — where calcium was identified as a ligand-binding cofactor — and MC1R, giving an unusually direct structural account of why one scaffold can act in opposite directions at two subtypes.

  • Asp2-Lys7 side-chain lactam
  • D-2-naphthylalanine at position 4

Terminal features: N-terminal acetylation at Nle1, C-terminal amide at Lys7.

04

Molecular targets & mechanisms

05

Analytical considerations

Establishing the Asp2-Lys7 lactam requires NMR or a validated orthogonal method; disulfide reduction is not a ring-opening strategy for a lactam and will not report on it. Verify D-2-Nal stereochemistry and the naphthyl attachment position. The expected mass separates SHU9119 from Melanotan II but not from every stereochemical or positional isomer, and an MC4R antagonist response is supportive functional evidence rather than chemical identification.

06

Verified bibliography

  1. Determination of the melanocortin-4 receptor structure identifies Ca(2+) as a cofactor for ligand binding.

    Yu J, Gimenez LE, Hernandez CC, Wu Y, Wein AH, Han GW, McClary K, Mittal SR, Burdsall K, Stauch B, Wu L, Stevens SN, Peisley A, Williams SY, Chen V, Millhauser GL, Zhao S, Cone RD, Stevens RC

    Science (New York, N.Y.) · 2020-04-24 · Journal Article

    current
  2. Structural mechanism of calcium-mediated hormone recognition and Gβ interaction by the human melanocortin-1 receptor.

    Ma S, Chen Y, Dai A, Yin W, Guo J, Yang D, Zhou F, Jiang Y, Wang MW, Xu HE

    Cell research · 2021-08-27 · Journal Article

    current
  3. Dissection of the anti-inflammatory effect of the core and C-terminal (KPV) alpha-melanocyte-stimulating hormone peptides.

    Getting SJ, Schiöth HB, Perretti M

    The Journal of pharmacology and experimental therapeutics · 2003-05-15 · Journal Article

    current

10

Methodology & citation verification

Reference identity is checked against official PubMed metadata. Local deterministic receipts bind each normalized title and canonical metadata record to its verification date. Scientific values remain absent when an authoritative source has not been verified.

Read the full methodology →